Trial · NCT05016076
Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial
NCT05016076, Not applicable, Withdrawn, YingHsuanTai
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial. Trials, record NCT05016076. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05016076
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial
- NCT number
- NCT05016076
- Status
- Withdrawn
- Phases
- Not applicable
- Enrollment
- 0 participants, actual
- Lead sponsor
- YingHsuanTai
- Conditions
- Obesity, Bariatric Surgery Candidate, Tracheal Intubation Morbidity, Nausea and Vomiting, Postoperative, Hyperglycemia Drug Induced, Gastric Reflux
- Interventions
Dexamethasone 8 mg, Applied inspiratory pressure (10, 15, 20, or 25 cmH2O), Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy, Goal-directed hemodynamic therapy targeting cardiac index, Placebo (0.9% sodium chloride)
- First posted
- 2021-08-23
- Last updated
- 2022-05-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Substudy 1: Number of participants developing postoperative nausea and vomiting | The first 24 postoperative hour | Primary outcome is postoperative nausea and vomiting, which includes any nausea, emetic episodes (retching or vomiting), or both during the first 24 postoperative hour. At the 2nd and 24th postoperative hours, trained investigators who are blinded to the group allocation will record the number of emetic episodes, the time each one occurs, and self-reported worst nausea episode during the preceding duration on an 11-point scale (0: no nausea and 10: the most severe nausea). |
| Primary | Substudy 2: The threshold inspiratory pressure for gastric insufflation | Within 2 min after induction of anesthesia | Primary outcome is the episode of gastric insufflation. The ultrasonographic diagnosis of gastric insufflation is defined as the presence of an acoustic shadow phenomenon and/or a comet-tail artifact into the antrum. A typical whoosh sound with gurgling while auscultating over the epigastrium defines the diagnosis of gastric insufflation by auscultation method. |
| Primary | Substudy 3: The best glottis visualization, graded according to Cormack and Lehane's classification | From the induction of anesthesia to the 24th postoperative hours | Primary outcome is the best glottis visualization, graded according to Cormack and Lehane's classification with external laryngeal pressure applied. The minimum and maximum values of Cormack and Lehane's grade are I and IV, respectively. Glottic views graded as III or IV are regarded as difficult. |
| Primary | Substudy 4: Number of participants developing postoperative major complications | Within 30 days after surgery | Primary outcome is a composite of major complications according to the European Perioperative Clinical Outcome definitions within 30 days after surgery, including myocardial ischemia or infarction, arrhythmia, acute kidney injury, gastrointestinal bleeding, anastomotic breakdown, surgical site infection, and hospital-acquired pneumonia. Any events of the above complications will be determined and analyzed aggregately and separately. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05016076
GET https://conductscience.org/api/trials/v1/NCT05016076/registered